We also observed an association of high ITGAV expression with poor survival prognosis in patients with diverse cancer types (Fig. 1h; source: Gene Expression Profiling Interactive Analysis (GEPIA), including breast carcinoma, pancreatic adenocarcinoma, lung adenocarcinoma, hepatocellular carcinoma and glioma; total: ~3,700 patients)31, highlighting the requirement for ITGAV in cancer progression. This evidence concerns the gene ITGAV and pancreatic adenocarcinoma.